Company profile
INHIBRX BIOSCIENCES, INC.
NASDAQ:INBXBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| ORDASTOBART | phase2_3 | — | 1 | active |
| OZEKIBART | phase2 | — | 2 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06295731 | phase2_3 | active_not_recruiting | 2024-05-14 | 2029-05-01 | Inhibrx Biosciences, Inc | INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC |
| NCT03715933 | phase1 | recruiting | 2018-10-08 | 2028-12-01 | Inhibrx Biosciences, Inc | Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas |
| NCT03815396 | phase1 | completed | 2019-07-19 | 2022-08-18 | Inhibrx Biosciences, Inc | Phase 1 Study to Assess the Safety, PK and PD of INBRX-101 in Adults With Alpha-1 Antitrypsin Deficiency |
| NCT03809624 | phase1 | terminated | 2019-01-30 | 2024-10-03 | Inhibrx Biosciences, Inc | Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer |
| NCT04198766 | phase1_2 | recruiting | 2019-12-10 | 2033-07-01 | Inhibrx Biosciences, Inc | Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) |
FDA applications (0)
No records yet.